ClinicalTrials.gov
ClinicalTrials.gov Menu

Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00072319
Recruitment Status : Completed
First Posted : November 6, 2003
Last Update Posted : March 4, 2013
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Pharmacia
Amgen
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : November 2006
  Actual Study Completion Date : November 2006